A Multicenter, Open-label, Phase II Clinical Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics (PK), and Immunogenicity of the Combination Therapy of SYS6026 in the Treatment of Advanced Solid Tumors

NCT07684261 · clinicaltrials.gov ↗

NOT_YET_RECRUITING

Status

186

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor

Interventions

DRUG: SYS6026 combined with Enlonstobart therapy

Sponsor

CSPC Megalith Biopharmaceutical Co.,Ltd.